NuVasive Q4 sales dip 6%, submits Pulse for approval: 6 notes

Alan Condon -   Print  |

NuVasive posted net sales of $291.8 million in the fourth quarter, a 6 percent decrease compared to the same period in 2019.

Six notes:

1. Fourth-quarter net income was $30.4 million on a non-GAAP basis, down from $38.5 million in the fourth quarter of the prior year.

2. NuVasive reported a 10.1 percent decrease in full-year net sales to $1.05 year over year.

3. For the quarter ended Dec. 31, free cash flow was $44.8 million compared to $46.3 million in 2019.

4. COVID-19 continues to have a negative effect on elective surgeries and patient sentiment, "particularly within the U.S. market, which increased late in the fourth quarter," NuVasive CEO J. Christopher Barry said in a Feb. 24 news release.

5. NuVasive said it plans to advance its C360 portfolio after acquiring Simplify Medical for $150 million.

6. The company said it has submitted its application for FDA clearance of its Pulse system and its associated robotics, which it plans to launch this summer.

More articles on devices:
11 spine device companies to watch in 2021
FDA clears two surgical robots focused on imaging, spine
These CMS changes would significantly improve spine care: 6 surgeons weigh in

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers